Regencell Bioscience Holdings (RGC) Short term Debt (2020 - 2021)
Regencell Bioscience Holdings (RGC) posted Short term Debt of $431969.0 for Q2 2021, down 85.93% on a QoQ basis from $3.1 million in Q2 2020, and down 85.93% year-over-year from $3.1 million in Q2 2020.
Regencell Bioscience Holdings (RGC) Short term Debt (2020 - 2021) Analysis & Trends
Regencell Bioscience Holdings' Short term Debt history runs 2 years deep, the most recent figure standing at $431969.0 for Q2 2021.
- Quarterly Short term Debt fell 85.93% year-over-year to $431969.0 in Q2 2021, while the trailing twelve-month figure through Jun 2021 was $431969.0 (down 85.93% YoY) and the FY2021 annual result came in at $431969.0, down 85.93% from the prior year.
- Short term Debt was $431969.0 for Q2 2021 at Regencell Bioscience Holdings, down from $3.1 million in the prior quarter.
- Across five years, Short term Debt topped out at $3.1 million in Q2 2020 and bottomed at $431969.0 in Q2 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Regencell Bioscience Holdings | 2.78 Bn | 2.78 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 431,969.00 |
| Jun 30, 2020 | 3.07 Mn |